Background Trofile is a clinically validated HIV-1 co-receptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Trofile determines whether a patient virus population is CCR5 (R5), CXCR4 (X4) or dual (R5/ X4)/mixed (D/M)-tropic and has demonstrated utility in clinical trials of CCR5 antagonists including maraviroc and vicriviroc. Existing studies suggest that detection of patients with lower levels of CXCR4-using variants may further optimize patient selection for CCR5 antagonist therapy. We therefore developed an enhanced sensitivity Trofile assay with improved ability to detect low levels of CXCR4-using virus.
No takes yet. Share an insight, caveat, or question.
Trinh et al. (2008) studied this question.